OXYBUTYNIN CHLORIDE | A207138 | ACCORD HEALTHCARE INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Foley & Lardner LLP FDA-2019-P-4507 · 3 docket documents Foley & Lardner LLP filed a citizen petition under Section 505(j) requesting that the FDA designate the Accord Healthcare Inc. ANDA for Oxybutynin Chloride Extended Release Tablets 15 mg as an additional reference standard because the original reference listed drug, DITROPAN XL, is discontinued and | Other | 2019-09-26 | Withdrawn | Foley & Lardner LLP |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0875
per ea
Lowest NADAC/Unit
$0.0875
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 16729031716OXYBUTYNIN CL ER 5 MG TABLET | $0.0875 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.